The costs required to reduce the risk of sickle cell disease are beyond the reach of most individuals in India and sub-Saharan Africa, where the disease is most prevalent, says a new Commission published in The Lancet Haematology journal.
The Commission publishes shortly after a recent study in the same journal found that the highest burden of sickle cell disease (SCD) disability was concentrated in western and central sub-Saharan Africa and India.
The authors of the Commission also noted that there is a shortage of healthcare and scientific professionals with expertise in SCD, as well as a lack of trials aimed at developing novel treatments in these countries.
